Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response of nebulized EP-101 (SUN101) in moderate to severe COPD
NCT01426009Phase 2Completed
- Sponsor
- Sunovion
- Start
- Aug 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Sunovion. Started Aug 2011; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01426009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01426009.